Company*
(Country; Symbol)
Company*
(Country; Symbol)
Type/Product Area
Terms/Details (Date)
July
Access Pharmaceuticals Inc. (OTC BB:ACCP)
Unnamed biotechnology company
Pre-licensing feasibility agreement with an unnamed biotechnology company to develop an oral formulation of its currently marketed injectable drugs
Access will use its Cobalamin oral drug delivery technology to develop oral formulations of the drug for preclinical testing; a successful formulation will be subject to a full-licensing agreement (7/19)
Amorfix Life Sciences Ltd. (Canada; TSX:AMF)
Biogen Idec Inc. (BIIB)
Licensing agreement for exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis monoclonal antibodies
The antibodies have shown efficacy in animal models of ALS; Biogen Idec will complete development and prepare for clinical trials; Amorfix will receive $1M up front and is eligible for milestones and royalties (7/19)
Ampio Pharmaceuticals Inc. (OTC BB:AMPE)
DMI BioSciences Inc.*
Deal giving Ampio access to all rights, royalties and patents associated with DMI's drugs for male sexual dysfunction, including premature ejaculation, and combination drugs to treat premature ejaculation and erectile dysfunction
Ampio also gets Phase III trial data accumulated for the PE drugs; financial terms were not disclosed (7/28)
Aptuit Inc.*
Siena Biotech SpA* (Italy)
Strategic partnership in which Siena Biotech will take a minority stake in Aptuit's Italian operations in Verona, Italy
Aptuit will become a provider of choice for Siena Biotech's development pipeline; they will work in the areas of Alzheimer's disease, Huntington's disease and oncology (7/30)
Aquapharm
Biodiscovery
Ltd.* (Scotland)
Albany Molecular
Research Inc.
(AMRI)
Research …
No comments:
Post a Comment